Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 907-913

  De Marco, Cinzia ^a   Zaffaroni, Nadia ^a   Comijn, Elizabeth ^b   Tesei, Anna ^c   Zoli, Wainer ^c   Peters, Godefriedus J ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

C1311; Cell cycle; Cytotoxicity; Doxorubicin; Imidazoacridinones; Taxol

Indexed keywords

AMINOACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DOXORUBICIN; IMIDACRINE; LISSAMINE RHODAMINE B; PACLITAXEL; RHODAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECT; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; NEOPLASM; PATHOLOGY;

AMINOACRIDINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CDC2 PROTEIN KINASE; CELL DIVISION; CELL PROLIFERATION; CYCLIN B; DOXORUBICIN; DRUG THERAPY, COMBINATION; G2 PHASE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NEOPLASMS; PACLITAXEL; RHODAMINES; TUMOR CELLS, CULTURED;

EID: 35848964811     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.907     Document Type: Article

References (25)

1. Cholody WM, Martelli S, Paradziej-Lukowicz J and Konopa J: 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33: 49-52, 1990.
2. Berger B, Marquardt H and Westendorf J: Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56: 2094-2104, 1996. (Pubitemid 26120600)
3. Calabrese CR, Bibby MC, Double JA and Loadman PM: Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemother Pharmacol 42: 379-385, 1998.
4. Burger AM, Double JA, Konopa J and Bibby MC: Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74: 1369-1374, 1996.
5. Mazerska Z, Dziegielewski J and Konopa J: Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA. Biochem Pharmacol 61: 685-694, 2001.
6. Mazerska Z, Gorlewska K, Kraciuk A and Konopa J: The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives. Chem Biol Interact 115: 1-22, 1998.
7. Mazerska Z, Sowinski P and Konopa J: Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311. Biochem Pharmacol 66: 1727-1736, 2003. (Pubitemid 37249317)
8. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A and Konopa J: Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63: 1653-1662, 2002.
9. Skladanowski A, Plisov SY, Konopa J and Larsen AK: Inhibition of DNA topoisomerase II by imidazoacridinones, new anti-neoplastic agents with strong activity against solid tumors. Mol Pharmacol 49: 772-780, 1996.
10. Burger AM, Jenkins TC, Double JA and Bibby MC: Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81: 367-375, 1999.
11. Hyzy M, Bozko P, Konopa J and Skladanowski A: Anti-tumour imidazoacridinone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 69: 801-802, 2005.
12. Augustin E, Wheatley DN, Lamb J and Konopa J: Imidazoacridinones arrest cell cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol 38: 39-44, 1996. (Pubitemid 126423152)
13. Lamb J and Wheatley DN: Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbations. Br J Cancer 74: 1359-1368, 1996.
14. Mastbergen SC, Duivenvoorden I, Versteegh RT and Geldof AA: Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs. Anticancer Res 20: 1833-1838, 2000.
15. Lewin B: Driving the cell cycle: M phase kinase, its partners and substrates. Cell 61: 743-752, 1990.
16. Skehan P, Storeng R, Monks A, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990. (Pubitemid 20213250)
17. Solomon MJ, Glotzer M, Lee TH, Philippe M and Kirschner MW: Cyclin activation of p34cdc2. Cell 63: 1013-1024, 1990.
18. Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG and Double JA: Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 37: 1953-1962, 2001.
19. Warr JR, Quinn DM, Double JA and Bibby MC: Low level multidrug resistance expression to C1311, a potential clinical candidate. Br J Cancer 75 (Suppl): 33, 1996.
20. Karpeh MS, Kelsen DP and Tepper JE: Cancer of the stomach. In: Cancer. Principles and Practice of Oncology. De Vita VT, Hellman S, and Rosenberg SA (eds). 6th edition. Lippincot Williams and Wilkins, Philadelphia, pp1092-1125, 2001.
21. Uetsuka H, Haisa M, Kimura M, et al: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 10: 27-35, 2003.
22. Suganuma K, Kubota T, Saikawa Y, et al: Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 94: 355-359, 2003.
23. Ling Y-H, El-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized p388 cells. Mol Pharmacol 49: 832-841, 1996.
24. Borgne A and Meijer L: Sequential dephosphorylation of p34cdc2 on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem 271: 27847-27854, 1996.
25. Kao GD, McKenna WG and Muschel RJ: p34cdc2 kinase activity is excluded from the nucleus during the radiation-induced G2 arrest in HeLa cells. J Biol Chem 274: 34779-34784, 1999.